Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
Clinical trial NCT01350401 · TERMINATED
Trial details
- NCT number
- NCT01350401
- Sponsor
- Adaptimmune
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-01
- Primary completion
- 2016-02-17
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.